Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Magnetic Control of Polymorphism in Pharmaceutical Compounds

Objective

This H2020-FETOPEN-2016-2017 proposal initiates a major international effort to direct polymorphism in pharmaceutical compounds through crystallizing in high magnetic fields. The ability to direct polymorphism would have a transformative effect on almost all pharmaceutical compounds, and hence on society.

It is proposed that MagnaPharm will drive forward innovation in pharmaceuticals by exploiting our new discovery that the polymorph and properties of carbamazepine, indomethacin and coronene can be controlled through the application of magnetic fields. We will apply our method to a range of pharmaceutical compounds, as guided by our project partner AstraZeneca, one of the largest pharmaceutical companies in the world. We will initially target 12 of the most high-profile, high-worth generic drugs with the aim of controllably synthesizing the desired polymorph of each (the lowest-energy polymorph and/or most processable form with desired properties). We aim for this goal via an international multidisciplinary approach centred around our discovery, underpinned by the development of a profound theoretical understanding of the effects of magnetic fields on organic crystal growth, that will direct the synthetic effort, all drawing on results from cutting edge spectroscopic and crystallographic characterisations.

With the 12 representative generic drug molecules targeted in the initial stages of MagnaPharm responsible for €18 billion of sales per year worldwide, and the development of many new pharmaceuticals being hampered by solid form issues, control over the production of the most pharmaceutically desired crystal is a truly paradigm-shifting prospect.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

RIA - Research and Innovation action

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-FETOPEN-2016-2017

See all projects funded under this call

Coordinator

UNIVERSITY OF BRISTOL
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 1 195 677,50
Address
BEACON HOUSE QUEENS ROAD
BS8 1QU Bristol
United Kingdom

See on map

Region
South West (England) Gloucestershire, Wiltshire and Bristol/Bath area Bristol, City of
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 1 195 677,50

Participants (3)

My booklet 0 0